J&J invests in Clarimedix nitric oxide therapy; Eisai and Nobelpharma launch water-soluble prodrug seizure treatment;

> Clarimedix has nailed down an undisclosed investment from Johnson & Johnson ($JNJ) to fund a proof-of-concept study for its nitric oxide donor therapy, which triggers NO production through a light emitting diode patch applied over the skin. Release

> DSM, a biomedical material sciences company, has joined the European Union-funded PANOPTES consortium to help develop tailored amino acid-based polymers toward sustained drug delivery for the posterior segment of the eye. Story

> Eisai and Nobelpharma Co. are launching in Japan a water-soluble prodrug version of phenytoin injection, a long-used epilepsy and anti-seizure treatment. This version is intended to reduce skin irritation during intravenous infusion and to be easier for the patient to handle. Release

> Shire has signed a deal with Prasco Laboratories allowing Prasco to distribute a generic version of its Carbatrol extended-release capsules, which are indicated to treat certain types of seizures and nerve pain. Article

> Engineered BioPharmaceuticals is profiled on its efforts to develop dry-powdered versions of drugs that can be delivered in inhalers, nasal devices or syringes. Report